Inhaled Beclomethasone Dipropionate Research Articles

Comparison of the Effects of Beclomethasone Dipropionate and Budesonide in the Treatment of Children with Mild, Persistent Asthma.

ObjectiveTo compare the mean change in peak expiratory flow values in children receiving inhaled beclomethasone dipropionate versus inhaled budesonide in the treatment of mild persistent asthma.MethodThe medical records of 60 patients from the outpatient department (OPD)/emergency room (ER), National Institute of Child Health, Karachi, who received beclomethasone dipropionate (BDP) 200 µg one puff and budesonide (BUD) 200 µg one puff twice a day for treatment of mild persistent asthma from March 10, 2020, to August 10, 2020, were explored.ResultsThe mean age of children was 10.56 ± 3.01 years in the BUD group and 10.05 ± 3.54 years in the BDP group. The mean change in peak expiratory flow % in the BUD group was 15.69 ± 3.59%, and in the BDP group, it was 13.59 ± 4.26% (P-value=0.04)ConclusionBDP and budesonide (BUD) were both found to be effective for the treatment of mild persistent asthma in children. However, we found that BUD had better efficacy compared to BDP.

Breathomics in Asthmatic Children Treated with Inhaled Corticosteroids.

Background: “breathomics” enables indirect analysis of metabolic patterns underlying a respiratory disease. In this study, we analyze exhaled breath condensate (EBC) in asthmatic children before (T0) and after (T1) a three-week course of inhaled beclomethasone dipropionate (BDP). Methods: we recruited steroid-naive asthmatic children for whom inhaled steroids were indicated and healthy children, evaluating asthma control, spirometry and EBC (in asthmatics at T0 and T1). A liquid-chromatography–mass-spectrometry untargeted analysis was applied to EBC and a mass spectrometry-based target analysis to urine samples. Results: metabolomic analysis discriminated asthmatic (n = 26) from healthy children (n = 16) at T0 and T1, discovering 108 and 65 features relevant for the discrimination, respectively. Searching metabolomics databases, seven putative biomarkers with a plausible role in asthma biochemical–metabolic processes were found. After BDP treatment, asthmatic children, in the face of an improved asthma control (p < 0.001) and lung function (p = 0.01), showed neither changes in EBC metabolomic profile nor in urinary endogenous steroid profile. Conclusions: “breathomics” can discriminate asthmatic from healthy children, with prostaglandin, fatty acid and glycerophospholipid as putative markers. The three-week course of BDP—in spite of a significant clinical improvement—was not associated with changes in EBC metabolic arrangement and urinary steroid profile.

A comparison between effects of two medications on asthmatic child

Background: Asthma is a common chronic illness of childhood and it is the leading cause of childhood morbidity as measured by school absence, emergency department visit and hospitalization. All children with persistent asthma are in need for controller therapy. Beclomethasone dipropionate inhaler is corticosteroid medication used as controller of persistent asthma. Montelukast is a leukotrine receptor antagonist used as second line in controlling the symptoms of asthmatic child. Objective: comparison between the effects of beclomethasone dipropionate inhaler and montelukast on the total serum level of immunoblobulin E and Childhood Asthma Control Test in asthmatic children aged 4 -11 years. Methods: A randomized clinical trial was done in Children welfare Teaching Hospital from August 2017 to the end of October 2018. Ninety-seven patients were collected from asthma outpatient clinic aged 4-11 years with mild persistent asthma and randomly divided into beclomethasone group (51) patients and montelukast group (46) patients, the total serum IgE was done before initiation of treatment and another reading was done after 3 months. The score of symptoms control was evaluated by Childhood Asthma Control Test C-ACT after 1 month of treatment and another evaluation was done 2 months later. Results: There was significant reduction in total serum IgE level (21% for montelukast group and 27% for beclomethasone group after 3 months of treatment compared to base line IgE and there was significant improvement in Childhood C-ACT scores (16% for montelukast group and 24% for beclomethasone group) after 3 months of treatment compared to first month of treatment. There was significant improvement in beclomethasone group compared to montelukast group after three months of treatment.Conclusions: Both beclomethasone and montelukast are effective controllers for asthma symptoms and reducing total serum IgE level. Beclomethasone is better than montelukast in improving C-ACT scores.

The protective effect of beclomethasone dipropionate in the modeling of chronic obstructive pulmonary disease

The purpose of the study was to evaluate the protective effect of the inhaled glucocorticosteroids of beclomethasone dipropionate (BDP) using the experimental model of chronic obstructive pulmonary disease (COPD). Materials and Methods . The COPD model was reproduced in rats ( n = 30) during a discrete 60-day exposure to nitrogen dioxide, 9 individuals formed an intact group. Inhalation of BDP (50 micrograms per day) and control ( n = 15) placebo inhalation were performed for 60 days in the rats in the experimental group ( n = 15). The cell composition and cytokine enzymatic profile of bronchoalveolar lavage fluid (BALF), its content of secretory immunoglobulin A (sIgA) and surfactant protein D (SP-D) were determined by ELISA. Histological and morphometric lungs examination was performed. Results . Typical for COPD pathomorphological changes in the lungs were determined in the placebo group, the content of inflammatory cells and pro-inflammatory mediators in BALF increased, the functional activity of bronchoalveolar epithelium (SP-D, sIgA) deteriorated. There was a clear trend in the activity of neutrophilic-lymphocytic inflammation decrease with normalization of the profile of pro-inflammatory cytokines and enzymes in BALF In the group of animals receiving BDP; there was also a restoration of the morphological structure of the bronchoalveolar epithelium and improvement of its functional activity. Conclusion . The using of BDP in rats with the experimental COPD model had an expressed anti-inflammatory effect associated with the activation of physiological repair processes in the lungs, manifested by the restoration of structural, immune barrier integrity and functional activity of the bronchoalveolar epithelium.

Effects of montelukast versus inhaled beclomethasone on asthma control and immunoglobulin-E levels in asthmatic children

Background: Beclomethasone dipropionate inhaler is a corticosteroid medication used as the controller of persistent asthma. Montelukast is a leukotriene receptor antagonist used as the second-line in controlling the symptoms of the asthmatic child. Objective: The objective of this study is to determine the comparison between the effects of beclomethasone dipropionate inhaler and montelukast on the total serum level of immunoglobulin E (IgE) and childhood asthma control test (C-ACT) in asthmatic children. Patients and Methods: A randomized clinical trial was done in Kerbala Teaching Hospital of pediatric from August 2014 to the end of October 2015, 97 patients were collected from asthma outpatient clinic aged 4 to 11 years with mild persistent asthma and randomly divided into beclomethasone group (51 patients) and montelukast group (46 patients), the total serum IgE was done before the initiation of treatment, and another reading was done after 3 months. The score of symptoms control was evaluated by C-ACT after 1 month of treatment, and another evaluation was done 2 months later. Results: There was a significant reduction in total serum IgE level (21% for montelukast group and 27% for beclomethasone group) after 3 months of treatment compared to baseline IgE, and there was significant improvement in childhood C-ACT scores (16% for montelukast group and 24% for beclomethasone group) after 3 months of treatment compared to the 1st month of treatment. There was a significant improvement in the beclomethasone group compared to the montelukast group after 3 months of treatment. Conclusions: Both beclomethasone and montelukast are effective controllers for asthma symptoms and reducing the total serum IgE level. Beclomethasone is better than montelukast in improving C-ACT scores.

Treatment of Laryngeal Granulomas.

Introduction Laryngeal granulomas are benign, recurrent lesions of many causes (reflux, voice abuse, intubation, and idiopathic), which renders its treatment difficult. Objective To describe our experience in the treatment of laryngeal granulomas. Methods From 16 medical records of the patients with laryngeal granulomas seen between 2010 and 2017 in a university hospital, the following data were analyzed: age, gender, vocal and gastroesophageal symptoms, vocal overuse, intubation, treatments, videolaryngoscopy before and after the treatment. Results Gender: female, 10; male, 6. Age: between 20 and 60 years old (11). Etiology of the granulomas: intubation (9), reflux (4), idiopathic (3). The initial treatments adopted in all cases were: inhaled beclomethasone dipropionate 100 µg 12/12 hours (1 month), proton pump inhibitor, omeprazole 40 mg/day (2 months), and dietary and voice education. After this period, 10 patients (7 postintubation, 3 idiopathic) were submitted to surgery, since no improvements in the symptoms or in the lesions were seen. Of these, two recurred, requiring a second surgery, one of which recurred six times and received botulinum toxin A. Only one patient with granulomas due to laryngopharyngeal reflux presented no improvement in the symptoms nor in the lesion after the pharmacological treatment and had been submitted to microsurgery. All of the other patients with reflux granulomas were successfully treated with the drug treatment, and the longest treatment time for complete remission of the symptoms and of the lesions was 9 months. Conclusions In laryngeal granulomas caused by reflux, treatment with inhaled steroids and proton pump inhibitors proved to be effective, although prolonged. In postintubation and idiopathic granulomas, surgery was the best treatment.

Patient-Reported Outcomes And Quality Of Life Improvements In Patients With Asthma Receiving A New, Breath-Actuated Beclomethasone Dipropionate Inhaler

Patient-Reported Outcomes And Quality Of Life Improvements In Patients With Asthma Receiving A New, Breath-Actuated Beclomethasone Dipropionate Inhaler

Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects

Inhaled corticosteroids (ICSs) are the preferred treatment for achieving asthma control. However, little is known regarding the factors contributing to treatment response and whether treatment response differs by population group. We sought to assess behavioral, sociodemographic, and genetic factors related to ICS response among African American and European American subjects with asthma. Study participants were part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). The analytic sample included asthmatic subjects aged 12 to 56years with greater than 12% bronchodilator reversibility and percent predicted FEV1 of between 40% and 90%. Participants received 6weeks of inhaled beclomethasone dipropionate. The primary measure of ICS response was a change in Asthma Control Test (ACT) score; the secondary measure was a change in prebronchodilator FEV1. Adherence was measured with electronic monitors. Genetic ancestry was estimated for African American participants by using genome-wide genotype data. There were 339 study participants; 242 self-identified as African American and 97 as European American. Baseline ACT score, percent predicted FEV1, degree of bronchodilator response, and ICS adherence were significantly associated with ICS response. Abaseline ACT score of 19 or less was useful in identifying those who would respond, as evidenced by the significant dose-response relationship with ICS adherence. Neither self-reported race-ethnicity among all participants nor proportion of African ancestry among African American participants was associated with ICS responsiveness. Our findings suggest that baseline lung function measures and self-reported asthma control predict ICS response, whereas self-reported race-ethnicity and genetic ancestry do not.

ORAL montelukast versus inhaled beclomethasone in the prophylactic treatment of post ACUTE viral bronchiolitis wheezing

Methods This is a randomized, pilot study, involving infants ≤ 1 year of age hospitalized due to acute viral bronchiolitis. All patients with moderate-severe bronchiolitis (Wang score ≥ 8) are eligible to initiate the study. At hospital discharge, recruited patients are randomized into three study groups conventional treatment, oral montelukast (MK) or inhaled beclomethasone dipropionate (BDP) and directed to monthly follow-up appointments for 6 months. We aim to determine the potential benefit of inhaled BDP and oral MK in the natural history of post bronchiolitis wheezing. The primary variables are: need of hospitalization and number of visits to the emergency department (ED). The secondary variables are: number of days until first exacerbation, duration of hospitalization, number of asymptomatic days and need of bronchodilator and/or oral corticosteroid.

炎症性声帯疾患による音声障害のBeclomethasone Dipropionate Inhalerによる治療経験

炎症性声帯疾患による音声障害のBeclomethasone Dipropionate Inhalerによる治療経験

Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient

A series of semi-empirical equations were utilised to design two solution based pressurised metered dose inhaler (pMDI) formulations, with equivalent aerosol performance but different physicochemical properties. Both inhaler formulations contained the drug, beclomethasone dipropionate (BDP), a volatile mixture of ethanol co-solvent and propellant (hydrofluoroalkane-HFA). However, one formulation was designed such that the emitted aerosol particles contained BDP and glycerol, a common inhalation particle modifying excipient, in a 1:1 mass ratio. By modifying the formulation parameters, including actuator orifice, HFA and metering volumes, it was possible to produce two formulations (glycerol-free and glycerol-containing) which had identical mass median aerodynamic diameters (2.4μm±0.1 and 2.5μm±0.2), fine particle dose (⩽5μm; 66μg±6 and 68μg±2) and fine particle fractions (28%±2% and 30%±1%), respectively. These observations demonstrate that it is possible to engineer formulations that generate aerosol particles with very different compositions to have similar emitted dose and in vitro deposition profiles, thus making them equivalent in terms of aerosol performance. Analysis of the physicochemical properties of each formulation identified significant differences in terms of morphology, thermal properties and drug dissolution of emitted particles. The particles produced from both formulations were amorphous; however, the formulation containing glycerol generated particles with a porous structure, while the glycerol-free formulation generated particles with a primarily spherical morphology. Furthermore, the glycerol-containing particles had a significantly lower dissolution rate (7.8%±2.1%, over 180min) compared to the glycerol-free particles (58.0%±2.9%, over 60min) when measured using a Franz diffusion cell. It is hypothesised that the presence of glycerol in the emitted aerosol particles altered solubility and drug transport, which may have implications for BDP pharmacokinetics after deposition in the respiratory tract.

Comparative study of fluticasone propionate with budesonide and beclomethasone dipropionate in mild persistent bronchial asthma

Objective: To compare the efficacy and adverse effects of fluticasone propionate with that of budesonide and beclomethasone dipropionate in mild persistent cases of bronchial asthma. Methods: This was an open label, randomized parallel group study done in Government General and Chest Hospital, Hyderabad for a period of 12 weeks. Each group had 20 patients. The group I was given fluticasone propionate inhalation therapy 100μg twice daily. Group II was given budesonide inhalation therapy 200μg twice daily. Group III was given beclomethasone dipropionate inhalation therapy 200μg twice daily. Results: Symptomatic improvement was observed in all three groups. At end point, mean FEV1 in fluticasone propionate treatment group improved by 22.04% compared with 14.53% in budesonide and 12.02% in beclomethasone treatment groups. At end point, mean FVC value of the fluticasone propionate treatment group improved by 8.04% compared with 5.29% in budesonide and 4.27% in beclomethasone groups. Mean FEV1 / FVC also improved by 12.76% in the fluticasone propionate group compared with 8.63 % in budesonide and 7.45 % in beclomethasone groups. No adverse effects were reported in any of the treatment groups. Conclusion: This study showed that fluticasone propionate is superior to budesonide and beclomethasone in improving lung function, decreasing symptoms and need for rescue medication in mild persistent asthma

Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma

BackgroundShort-acting beta2-agonists like salbutamol and terbutaline are used as rescue medications for acute bronchoconstriction and relief of symptoms due to their rapid onset of action. The aim of this study was to assess whether inhaled beclomethasone dipropionate (BDP)/formoterol fumarate (FF) combination in extrafine formulation is non-inferior to salbutamol in the speed of reverting methacholine-induced bronchoconstriction and symptoms. MethodsFifty-six asthmatic patients were examined in a multicentre, randomised, double blind, double dummy, active treatment and placebo controlled three period cross-over study. On three different days, a single dose of BDP/FF 100/6 μg in pressurised metered-dose inhaler (pMDI) extrafine formulation or salbutamol 200 μg pMDI or placebo was inhaled after FEV1 had dropped by 30–45% with methacholine challenge. ResultsThe median time to recovery of FEV1 to 85% of baseline was similar for BDP/FF and salbutamol (3.66 and 2.15 min, respectively), but significantly longer for placebo (21.1 min). The planned analysis on adjusted mean time to recovery showed that the difference from methacholine-induced bronchoconstriction between BDP/FF and salbutamol was 3.82 min (95% confidence interval: −0.85 to 8.5), therefore greater than 3 min supposed in the study design. The difference between BDP/FF and salbutamol was not clinically significant. The two active treatments were also comparable in terms of the relief of symptoms (as assessed by the Borg dyspnoea scale). ConclusionsBDP/FF combination has a fast onset of action, similar to that of salbutamol, and may represent a good alternative as rescue medication in asthmatic patients.

Highlights in this issue

‘The hard problem’ of consciousness is why and how subjective experience arises from physical basis. In this issue, Hans Lou discusses the identification of neural events behind the emergence of consciousness, in particular awareness e.g. of the Danish Queen. Of special importance is the gamma synchrony, which is regulated by dopamine and other neurotransmitters. This system may be disturbed in autism, ADHD and schizophrenia (pp. 112–119). A well-established pain score (PIPP) was used to monitor discomfort during transport. Most babies showed signs of discomfort according to Cath Harrison and Liz McKechnie (pp. 143–147). See also article by Björn-Markus Karlsson et al (pp. 148–154) showing that sound and body vibration during neonatal transport exceed the recommended levels for adults. Coeliac disease was reported to be far more common among children in Sweden than in Denmark. This was attributed to the addition of gluten to infant formula. Now, Stine Dydensborg et al report from Denmark a more than fourfold increase in the incidence during the last ten years. However, this prevalence is still considerably lower than reported elsewhere, possibly due to less stringent criteria (pp. 179–184). See also article by Carl J Wingren et al. showing the association between low socio-economic status and coeliac disease in Sweden (pp. 185–191). Obesity in adults often leads to metabolic syndrome increasing the risk for type II diabetes and early cardiovascular disease. Rikke J Gøbel et al now report low-grade inflammation and elevated levels of several biomarkers of the metabolic syndrome in otherwise healthy Danish obese adolescents. This is an important finding and should lead to interventions to decrease the risk factors to prevent adult disease (pp. 192–200). See also article by Lone M Larsen et al. (pp. 201–207). Radiology, histology and short-term outcome of asymptomatic congenital thoracic malformations by Thomas Kongstad et al. (pp. 155–158). Systemic activity of inhaled beclomethasone dipropionate: a double-blind comparison of volume spacers by Ole D Wolthers et al. (pp. 159–163). Low 5-minute Apgar score in moderately preterm infants; association with subsequent death and cerebral palsy by Line V Jensen et al. (pp. e80–e82).

Evaluation of the combined effect of pranlukast during high-dose steroid inhalation.

In 40 patients with moderate to severe persistent adult asthma who had been requiring more than 1200 micrograms/day of beclomethasone dipropionate (CAS 5534-09-8, BDP) inhalation, the present study evaluated the combined effects of pranlukast (CAS 103177-37-3, Onon) during highdose steroid inhalation (20 in the pranlukast group and 20 in the control group). In the pranlukast group, 450 mg/day of pranlukast was administered. The course of these patients was monitored for 6 weeks during which the dose of BDP was decreased to 1/2 of the initial dose 2 weeks later and to 1/4 of the initial dose additional 4 weeks later. The dose of BDP was also decreased in the control group. The concomitant use of pranlukast significantly improved asthmatic symptoms and respiratory functions in asthmatic patients receiving high-dose steroid inhalation. Furthermore, the concomitant use of pranlukast significantly inhibited worsening of asthmatic symptoms, respiratory functions and parameters, which are frequently observed when the dose of inhalation steroids is decreased.

Use of Beclomethasone Dipropionate as Rescue Treatment for Children With Mild Persistent Asthma (TREXA): A Randomized, Double-Blind, Placebo-Controlled Trial

FD Martinez, VM Chinchilli, WJ Morgan. Lancet. 2011;377(9766):650–657 To determine the effectiveness of inhaled beclomethasone dipropionate when used as a rescue treatment for symptoms in children with mild persistent asthma. Children and adolescents aged 5 to 18 years with well-controlled mild persistent asthma were enrolled from 5 clinical centers in a 44-week, randomized, double-blind, placebo-controlled trial. Participants who remained well controlled during the 4-week run-in period were stratified according to clinical center and age group and randomly assigned to 1 of 4 treatments: twice-daily beclomethasone with beclomethasone plus albuterol as rescue (combined group); twice-daily beclomethasone with placebo plus albuterol as rescue (daily beclomethasone group); twice-daily placebo with beclomethasone plus albuterol as rescue (rescue beclomethasone group); and twice-daily placebo with …

Systemic activity of inhaled beclomethasone dipropionate: a double‐blind comparison of volume spacers

To which extent volume spacers may influence systemic activity of inhaled beclomethasone dipropionate (BDP) has not been evaluated. To assess whether the AeroChamber Plus™ spacer is equivalent to the Volumatic™ spacer for administration of inhaled hydroflouroalkane 134a propelled BDP in terms of lower leg growth rate (LLGR). Prepubertal children with mild asthma (n = 26, aged 6-14 years) were included in a 3-time periods of 2 weeks duration randomized double-blind cross-over study with a single-blind placebo run-in and two washout periods. LLGR was measured with the knemometer. Interventions were inhaled BDP hydroflouroalkane 134a pressurized metered dose inhaler 100 μg and 200 μg b.i.d. with the AeroChamber Plus and 200 μg b.i.d. with the Volumatic spacer. Beclomethasone dipropionate 200 μg b.i.d. from the AeroChamber Plus was non-inferior to BDP 200 b.i.d. from the Volumatic spacer as the lower margin of confidence interval of the difference between treatments (-0.18 to 0.13 mm/week) was greater than the prespecified lower limit for non-inferiority (-0.20 mm/week). UFC/creatinine data showed no statistically significant variations. The systemic activity of BDP, via the Volumatic™, and AeroChamber Plus™ spacers is similar. The AeroChamber Plus spacer may be used in children without risk of increasing systemic activity of BDP.

Beclomethasone dipropionate: A second chance for topical steroids as maintenance therapy in ileal Crohn's disease

One third of patientswith Crohn’s disease have ileitis at the time f diagnosis [1], and treatment of ileal Crohn’s disease remains a hallenge in clinical practice. Side effects and dependence resulting from systemic steroids se are relevant problems and prevent their long-term use. Thus, ther therapies with same anti-inflammatory properties, but with ower systemic activity and side effects achieved through an extenive first-pass metabolism, have been developed. Amongst these s budesonide. However, the latter failed to show superiority to lacebo to maintain remission at 1 year [2]. Hence, neither sysemic steroids nor budesonide are recommended as maintenance herapy in Crohn’s disease [3]. Inhaled beclomethasone dipropionate (BDP) is widely used n the management of asthma. BDP is characterized by an nti-inflammatory activity with a high topical efficacy, as a esult of rapid uptake by mucosal tissue, and high affinity for lucocorticosteroid receptors. Similarly to budesonide, its low sysemic bioavailability is achieved through an extensive first-pass etabolism. Oral controlled release formulation of BDP is contituted by a gastro-resistant methacrylate film coating and a odified release core of hydroxypropyl methylcellulose that disolves at pH values lower than 6.0, thus permitting a release in the istal small bowel and the colon [4]. In inflammatory bowel diseases, BDP has first showed its effiacy for ulcerative colitis when administrated as enema [5] or oral ormulation [6] in induction clinical trials. Only one retrospective tudy has evaluated maintenance therapy with oral BDP in mild o moderate Crohn’s disease [7]. It permitted to achieve clinical esponse at 24 weeks in 12 of 18 (66.7%) Crohn’s disease patients nd tomaintain remission in 15 of 16 (93.8%) patients whowere in emission at baseline [7]. In this current issue of Digestive and Liver Disease, Prantera t al. publish the first randomised, double-blind, double-dummy,

Formulation and evaluation and terbutaline sulphate and beclomethasone dipropionate inhalation mixtures in the rotahaler device

We report the use of low rugosity lactose, product of controlled crystallization of this carrier, in the formulation of terbutaline sulphate and beclomethasone dipropionate dry powder inhalers. The deposition patterns obtained with inhalation mixtures consisting of the modified lactose and each of the micronised drugs terbutaline sulphate and beclomethasone dipropionate have been used to assess the effect of the surface smoothing technique on aerosolised drug delivery. The ROTAHALER device and the Twin Impinger BP were used in the assessment. Drug deposited in the throat, stage 1 and stage 2 of the Twin Impinger BP was determined and used to assess the difference between commercial lactose and the modified lactose prepared. The respirable fraction obtained with inhalation mixtures containing the recrystallized lactose samples was higher compared with inhalation mixtures containing regular lactose BP.Keywords: Rotahaler device, terbutaline sulphate, beclomethasone dipropionate, inhalation mixtures, twin impinger BP, respirable fraction

Effectiveness of Russian inhaled corticosteroid beclomethasone in bronchial asthma patients

Summary. Results of efficacy and safety trial of Russian inhaled beclomethasone dipropionate BeclospirR in mild to moderate asthma have been shown in the article. The study involved 60 patients with asthma. During 3 months, clinical efficacy of BeclospirR was compared to that of another preparation of beclomethasone Beclasone Eco using the following common criteria: • clinical symptoms of asthma (patients' dairies); • daily need in short-acting bronchodilators; • peak flow rate; • level of asthma control; • spirometric parameters (FEV1 before and after inhalation of salbutamol); • safety of treatment with BeclospirR. The results demonstrated that BeclospirR was not inferior to Beclasone Eco. Moreover, BeclospirR in the daily dose of 1 000 μg had certain advantages against Beclasone Eco.